Citadel Advisors
ENVB icon

Citadel Advisors’s Enveric Biosciences ENVB Stock Holding History

Citadel Advisors’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3
Closed -$10K – 13155
2022
Q1 		$10K Sell
3
-2
-40% -$8.84K ﹤0.01% 13377
2021
Q4 		$43K Sell
5
-1
-17% -$14.1K ﹤0.01% 13325
2021
Q3 		$109K Buy
+6
New +$116K ﹤0.01% 12767

Other funds holding ENVB

AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Citadel Advisors's ENVB Position: Q4 2025 in Review

Citadel Advisors sold out of Enveric Biosciences (ENVB) in Q4 2025, closing a stake of 1,890 shares — an estimated $14.5K sold.

Citadel Advisors first reported a position in ENVB in Q4 2020 and held it in 11 quarters. The position peaked at $179K in Q3 2021. 11 funds tracked by Wall St. Rank hold ENVB as of Q4 2025.

  • Citadel Advisors reported no remaining Enveric Biosciences position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 1,890 Enveric Biosciences shares in Q4 2025, an estimated $14.5K.
  • Citadel Advisors first reported a position in Enveric Biosciences in Q4 2020 and held it in 11 quarters.
  • Citadel Advisors's Enveric Biosciences position peaked at $179K in Q3 2021.
  • 11 funds tracked by Wall St. Rank held Enveric Biosciences as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.